Classifying Pulmonary and Urinary High-grade Neuroendocrine Carcinoma by CK7 Immunohistochemistry
- PMID: 35603802
- DOI: 10.1097/PAI.0000000000001036
Classifying Pulmonary and Urinary High-grade Neuroendocrine Carcinoma by CK7 Immunohistochemistry
Erratum in
-
Classifying Pulmonary and Urinary High-grade Neuroendocrine Carcinoma by CK7 Immunohistochemistry: Erratum.Appl Immunohistochem Mol Morphol. 2025 May 1;33(3):193. doi: 10.1097/PAI.0000000000001255. Epub 2025 Mar 28. Appl Immunohistochem Mol Morphol. 2025. PMID: 40151053 No abstract available.
Abstract
High-grade neuroendocrine carcinoma (HGNEC) is subclassified into small cell carcinoma (SmCC) and large cell neuroendocrine carcinoma (LCNEC). Although both are clinically aggressive, the SmCC and LCNEC need to have different treatment strategies, and accurate pathologic diagnosis is challenging. We studied a large retrospective cohort (186 cases) of HGNEC of bladder and lung to investigate the abundance of cytokeratin (CK) 7 expression and staining pattern in SmCC and LCNEC. Overall, the pulmonary and urinary HGNEC exhibited several different CK7 staining patterns, including negative staining (n=28), dot-like staining (n=73), partial membranous staining (n=26), and complete membranous staining (n=60). Overall, 88.9% (44/49) of pulmonary SmCC and 88.0% (44/50) of urinary SmCC showed negative or dot-like patterns for CK7, while 90.8% (59/65) of pulmonary LCNEC and 72.7% (16/22) of urinary LCNEC showed partial or complete membranous patterns for CK7 (χ 2 =105.05, P <0.0001). The distinct staining patterns were also present in those mixed SmCC and LCNEC. In addition, the specimen types or fixation did not affect CK7 staining patterns. In conclusion, CK7 has a high differential value for SmCC and LCNEC and could help guide personalized treatment for patients.
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
G.W. received New Faculty Research Award from University of British Columbia. The remaining authors declare no conflict of interest.
References
-
- Hung YP. Neuroendocrine tumors of the lung: updates and diagnostic pitfalls. Surg Pathol Clin. 2019;12:1055–1071.
-
- Sanguedolce F, Calo B, Chirico M, et al. Urinary tract large cell neuroendocrine carcinoma: diagnostic, prognostic and therapeutic issues. Anticancer Res. 2020;40:2439–2447.
-
- Wang G, Xiao L, Zhang M, et al. Small cell carcinoma of the urinary bladder: a clinicopathological and immunohistochemical analysis of 81 cases. Hum Pathol. 2018;79:57–65.
-
- Gupta S, Thompson RH, Boorjian SA, et al. High grade neuroendocrine carcinoma of the urinary bladder treated by radical cystectomy: a series of small cell, mixed neuroendocrine and large cell neuroendocrine carcinoma. Pathology. 2015;47:533–542.
-
- Zhou HH, Liu LY, Yu GH, et al. Analysis of Clinicopathological Features and Prognostic Factors in 39 Cases of Bladder Neuroendocrine Carcinoma. Anticancer Res. 2017;37:4529–4537.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials